Repligen said it entered into a five-year deal to supply the product. Recombinant protein A is used in the process of making monoclonal antibodies, which are used to treat a range of conditions including cancer and rheumatoid arthritis.
Repligen has been supplying recombinant protein A to GE Healthcare for more than 10 years.
Repligen said there are currently more than 25 monoclonal antibodies that have received regulatory approval with more than 200 products in various stages of clinical development. The worldwide revenue from the class of drug exceeded $35 billion in 2009, the company added.
Shares of Repligen rose 3 cents to $3.57 in midday trading. The stock has traded between $3.40 and $5.85 over the last 52 weeks.
